KPV: A Research Overview

Introduction

Short peptide fragments of larger hormones are useful for identifying which part of a molecule is responsible for an observed activity. KPV is a classic example: a tripeptide from the C-terminus of α-MSH investigated for signaling effects in cell and animal models.

What Is KPV?

KPV is the tripeptide L-Lys-L-Pro-L-Val (≈342 Da), matching residues 11–13 of α-MSH, a 13-amino-acid peptide derived from pro-opiomelanocortin (POMC). Research materials are synthetic, sometimes with C-terminal amidation matching the parent hormone.

Why Is It Studied?

α-MSH acts through melanocortin receptors and has been studied for roles in pigmentation and immune signaling. KPV is studied to understand whether a minimal fragment can influence inflammatory signaling pathways, and whether such effects depend on melanocortin receptors.

Research Background

Reviews of α-MSH and related tripeptides summarize anti-inflammatory signaling effects observed in vitro and in vivo. A 2008 study reported that KPV is transported into intestinal epithelial cells by the di/tripeptide transporter PepT1 and reduced inflammatory markers in cell and mouse colitis models.

Evidence classification: KPV findings are in vitro and animal. Controlled human clinical data are not established.

Mechanism and Scientific Principles

• Cellular uptake via PepT1 in intestinal epithelial models (in vitro).
• Reduced NF-κB and MAPK pathway activation and pro-inflammatory cytokine expression in cell models (in vitro).
• Some activity reported to be independent of melanocortin receptor binding (in vitro).

Analytical and Experimental Considerations

• Very small peptides elute early in reverse-phase HPLC; method conditions must be adapted to retain them.
• Identity by mass spectrometry, including amidated versus free-acid forms.
• Counter-ions can be a large fraction of mass — see Peptide Purity vs Quantity.

For another small peptide studied in cell biology, see GHK-Cu: Laboratory Research Overview.

Limitations of Current Research

The evidence base is small and predominantly preclinical. Receptor-dependent and receptor-independent mechanisms are not fully resolved.

Frequently Asked Questions

Scientific References

1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. [In vitro / animal] View source (opens in new tab)
2. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. [Review] View source (opens in new tab)